Haematologica, Vol 92, Issue 5, 710-711 doi:10.3324/haematol.10910
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lech-Maranda, E.
Right arrow Articles by Robak, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lech-Maranda, E.
Right arrow Articles by Robak, T.

Lymphoproliferative Disorders

Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia

Ewa Lech-Maranda*,#, Przemyslaw Juszczynski*,#,@, Anna Szmigielska-Kaplon*, Krzysztof Jamroziak*, Ewa Balcerczak°, Tadeusz Robak*,

* Department of Hematology, Medical University of Lodz, Poland
° Department of Pharmaceutical Biochemistry, Medical University of Lodz, Poland

Correspondence: Tadeusz Robak, MD, PhD, Department of Hematology, Medical University of Lodz, Ciolkowskiego 2 str, 93-510 Lodz, Poland. Phone/fax: international +4842.6895191/6895192. E-mail: robaktad{at}csk.umed.lodz.pl

We investigated HLA DRB1 correlations with chronic lymphocytic leukemia (B-CLL) outcome in 90 patients. Neither of the alleles was associated with B-CLL clinical characteristics or mortality. HLA DRB1*01 and HLA DRB1*02-null were associated with shorter overall survival (p=0.007, p=0.002). Our results suggest that HLA-restricted adaptive immunity influences CLL outcome.

Key words: chronic lymphocytic leukemia, HLA class II, HLA DRB1, outcome.